Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus LUPRON DEPOT PED KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus LUPRON DEPOT PED KIT.
FACTREL vs LUPRON DEPOT-PED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Category C
Category C
GnRH Agonist
GnRH Agonist